지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2018.1
- 수록면
- 451 - 458 (8page)
이용수
초록· 키워드
오류제보하기
Purpose: To investigate the efficacy, safety, and anatomical outcomes associated with intravitreal anti-vascular endothelial growth factor (VEGF) treatment of retinopathy of prematurity (ROP). Methods: We performed a retrospective review of intravitreal anti-VEGF (bevacizumab or ranibizumab) treatment of 153 eyes (83 infants) diagnosed with ROP at two tertiary hospitals from June 2011 to January 2017. The primary outcome was the rate of recurrence requiring additional treatment; secondary outcomes included incidence of major complications and final refractive error. Results: A total of 101 eyes were treated with bevacizumab, and 52 with ranibizumab. The bevacizumab and ranibizumab groups were characterized by mean birthweights of 941.8 ± 296.1 and 1,257.7 ± 514.5 g, gestational ages at birth of 26.9 ± 1.9 and 28.1 ± 3.2 weeks, and postmenstrual ages at treatment of 40.4 ± 2.4 and 39.2 ± 2.3 weeks, respectively. The two groups differed significantly in birthweights and gestational ages at birth, but not in postmenstrual ages at treatment. The mean follow-up duration was 30.9 ± 18.4 months for the bevacizumab group, and 13.9 ± 12.5 months for ranibizumab. More cases were classified as zone 1 ROP in the ranibizumab group (44.2% vs. 11.9%, p < 0.001). Major surgical interventions included scleral encircling and vitrectomy (one and two eyes, respectively, both in the bevacizumab group). Retinal detachment was noted in one eye treated with bevacizumab. There was no significant difference in the most recent spherical equivalence for the two groups (+0.10 ± 3.66 and +0.22 ± 3.00 diopters for bevacizumab and ranibizumab, respectively). Univariable analysis revealed that only ROP stage influenced the occurrence of major complications (odds ratio, 9.046; p = 0.012). Conclusions: Intravitreal anti-VEGF treatment of ROP with both bevacizumab and ranibizumab achieved stable retinal vascularization with a low rate of complications and recurrence. Ranibizumab achieved similar anatomical outcomes as bevacizumab, without additional risk for major complications.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
망막색소상피세포와 혈관 신생에서 혈관내피성장인자 발현에 대한 알코올의 영향
Journal of Retina
2022 .05
-
Refractive Outcomes of 4-year-old Children after Intravitreal Anti-VEGF Versus Laser Photocoagulation for Retinopathy of Prematurity
Korean Journal of Ophthalmology
2019 .01
-
Postnatal weight gain in the first two weeks as a predicting factor of severe retinopathy of prematurity requiring treatment
Clinical and Experimental Pediatrics
2015 .01
-
Effects of Oxygen Saturation Fluctuations on Retinopathy in Infants Younger than 30 Weeks’ Gestational A
Neonatal medicine
2021 .01
-
Influence of vascular endothelial growth factor inhibition on simple renal cysts in patients receiving bevacizumab-based chemotherapy
Investigative and Clinical Urology
2015 .01
-
Intravitreal Bevacizumab for the Treatment of Optic Disc Edema in a Patient with POEMS Syndrome
Korean Journal of Ophthalmology
2015 .01
-
Clinical Parameters Work Well as Predictive Factors for Atezolizumab and Bevacizumab Treatment in Hepatocellular Carcinoma
Gut and Liver
2024 .07
-
Chronic Placental Inflammation as a Risk Factor of Severe Retinopathy of Prematurity
Journal of Pathology and Translational Medicine
2018 .01
-
Bevacizumab Induced Intestinal Perforation in Metastatic Colorectal Cancers
대한외과학회 학술대회 초록집
2018 .11
-
A Case of Refractory Acute Angle Closure Glaucoma after an Intravitreal Bevacizumab Injection
Korean Journal of Ophthalmology
2020 .01
-
Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis
Journal of Liver Cancer
2024 .03
-
Vision-related Quality of Life in Malaysian Children with Threshold and Prethreshold Retinopathy of Prematurity
Korean Journal of Ophthalmology
2022 .06
-
Massive Exudative Retinal Detachment Following Photodynamic Therapy and Intravitreal Bevacizumab Injection in Retinal Capillary Hemangioma
Korean Journal of Ophthalmology
2015 .01
-
A Comparative Study of Topical Mitomycin C, Cyclosporine, and Bevacizumab after Primary Pterygium Surgery
Korean Journal of Ophthalmology
2015 .01
-
Risk Factors for Retinopathy of Prematurity Requiring Laser Treatment in Preterm Infants Born Before 28 Weeks of Gestation
Neonatal medicine
2019 .01
-
Relation Between Absoute Nucelated Red Blood Cell Count at Birth and Retinopathy of Prematurity
Neonatal medicine
2016 .01
-
Retinopathy of Prematurity-assist: Novel Software for Detecting Plus Disease
Korean Journal of Ophthalmology
2017 .01
-
Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells
Korean Journal of Ophthalmology
2018 .01
-
Intravitreal Bevacizumab for the Treatment of Choroidal Neovascularization after Eyeball Perforation during Retrobulbar Anesthesia
Korean Journal of Ophthalmology
2021 .01
-
Natural Short-term Course of Recurrent Macular Edema Following Intravitreal Bevacizumab Therapy in Branch Retinal Vein Occlusion
Korean Journal of Ophthalmology
2017 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0